Cargando…
Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melanoma (NCT00769704)
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4292568/ http://dx.doi.org/10.1186/2051-1426-2-S3-P263 |
| _version_ | 1782352502244507648 |
|---|---|
| author | Andtbacka, Robert HI Collichio, Frances A Amatruda, Thomas Senzer, Neil Chesney, Jason Delman, Keith Spitler, Lynn Puzanov, Igor Agarwala, Sanjiv Milhem, Mohammed Harrington, Kevin Middleton, Mark Li, Ai Shilkrut, Mark Coffin, Robert Kaufman, Howard |
| author_facet | Andtbacka, Robert HI Collichio, Frances A Amatruda, Thomas Senzer, Neil Chesney, Jason Delman, Keith Spitler, Lynn Puzanov, Igor Agarwala, Sanjiv Milhem, Mohammed Harrington, Kevin Middleton, Mark Li, Ai Shilkrut, Mark Coffin, Robert Kaufman, Howard |
| author_sort | Andtbacka, Robert HI |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4292568 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2014 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-42925682015-01-15 Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melanoma (NCT00769704) Andtbacka, Robert HI Collichio, Frances A Amatruda, Thomas Senzer, Neil Chesney, Jason Delman, Keith Spitler, Lynn Puzanov, Igor Agarwala, Sanjiv Milhem, Mohammed Harrington, Kevin Middleton, Mark Li, Ai Shilkrut, Mark Coffin, Robert Kaufman, Howard J Immunother Cancer Poster Presentation BioMed Central 2014-11-06 /pmc/articles/PMC4292568/ http://dx.doi.org/10.1186/2051-1426-2-S3-P263 Text en Copyright © 2014 I. Andtbacka et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Poster Presentation Andtbacka, Robert HI Collichio, Frances A Amatruda, Thomas Senzer, Neil Chesney, Jason Delman, Keith Spitler, Lynn Puzanov, Igor Agarwala, Sanjiv Milhem, Mohammed Harrington, Kevin Middleton, Mark Li, Ai Shilkrut, Mark Coffin, Robert Kaufman, Howard Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melanoma (NCT00769704) |
| title | Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melanoma (NCT00769704) |
| title_full | Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melanoma (NCT00769704) |
| title_fullStr | Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melanoma (NCT00769704) |
| title_full_unstemmed | Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melanoma (NCT00769704) |
| title_short | Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melanoma (NCT00769704) |
| title_sort | final planned overall survival (os) from optim, a randomized phase iii trial of talimogene laherparepvec (t-vec) versus gm-csf for the treatment of unresected stage iiib/c/iv melanoma (nct00769704) |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4292568/ http://dx.doi.org/10.1186/2051-1426-2-S3-P263 |
| work_keys_str_mv | AT andtbackaroberthi finalplannedoverallsurvivalosfromoptimarandomizedphaseiiitrialoftalimogenelaherparepvectvecversusgmcsfforthetreatmentofunresectedstageiiibcivmelanomanct00769704 AT collichiofrancesa finalplannedoverallsurvivalosfromoptimarandomizedphaseiiitrialoftalimogenelaherparepvectvecversusgmcsfforthetreatmentofunresectedstageiiibcivmelanomanct00769704 AT amatrudathomas finalplannedoverallsurvivalosfromoptimarandomizedphaseiiitrialoftalimogenelaherparepvectvecversusgmcsfforthetreatmentofunresectedstageiiibcivmelanomanct00769704 AT senzerneil finalplannedoverallsurvivalosfromoptimarandomizedphaseiiitrialoftalimogenelaherparepvectvecversusgmcsfforthetreatmentofunresectedstageiiibcivmelanomanct00769704 AT chesneyjason finalplannedoverallsurvivalosfromoptimarandomizedphaseiiitrialoftalimogenelaherparepvectvecversusgmcsfforthetreatmentofunresectedstageiiibcivmelanomanct00769704 AT delmankeith finalplannedoverallsurvivalosfromoptimarandomizedphaseiiitrialoftalimogenelaherparepvectvecversusgmcsfforthetreatmentofunresectedstageiiibcivmelanomanct00769704 AT spitlerlynn finalplannedoverallsurvivalosfromoptimarandomizedphaseiiitrialoftalimogenelaherparepvectvecversusgmcsfforthetreatmentofunresectedstageiiibcivmelanomanct00769704 AT puzanovigor finalplannedoverallsurvivalosfromoptimarandomizedphaseiiitrialoftalimogenelaherparepvectvecversusgmcsfforthetreatmentofunresectedstageiiibcivmelanomanct00769704 AT agarwalasanjiv finalplannedoverallsurvivalosfromoptimarandomizedphaseiiitrialoftalimogenelaherparepvectvecversusgmcsfforthetreatmentofunresectedstageiiibcivmelanomanct00769704 AT milhemmohammed finalplannedoverallsurvivalosfromoptimarandomizedphaseiiitrialoftalimogenelaherparepvectvecversusgmcsfforthetreatmentofunresectedstageiiibcivmelanomanct00769704 AT harringtonkevin finalplannedoverallsurvivalosfromoptimarandomizedphaseiiitrialoftalimogenelaherparepvectvecversusgmcsfforthetreatmentofunresectedstageiiibcivmelanomanct00769704 AT middletonmark finalplannedoverallsurvivalosfromoptimarandomizedphaseiiitrialoftalimogenelaherparepvectvecversusgmcsfforthetreatmentofunresectedstageiiibcivmelanomanct00769704 AT liai finalplannedoverallsurvivalosfromoptimarandomizedphaseiiitrialoftalimogenelaherparepvectvecversusgmcsfforthetreatmentofunresectedstageiiibcivmelanomanct00769704 AT shilkrutmark finalplannedoverallsurvivalosfromoptimarandomizedphaseiiitrialoftalimogenelaherparepvectvecversusgmcsfforthetreatmentofunresectedstageiiibcivmelanomanct00769704 AT coffinrobert finalplannedoverallsurvivalosfromoptimarandomizedphaseiiitrialoftalimogenelaherparepvectvecversusgmcsfforthetreatmentofunresectedstageiiibcivmelanomanct00769704 AT kaufmanhoward finalplannedoverallsurvivalosfromoptimarandomizedphaseiiitrialoftalimogenelaherparepvectvecversusgmcsfforthetreatmentofunresectedstageiiibcivmelanomanct00769704 |